Cargando…
NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways
Autores principales: | Honda, Ayumi, Kuramoto, Kazuya, Niwa, Tomoko, Naito, Haruna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018113/ https://www.ncbi.nlm.nih.gov/pubmed/29941953 http://dx.doi.org/10.1038/s41408-018-0098-z |
Ejemplares similares
-
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms
por: Nakaya, Y, et al.
Publicado: (2011) -
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
por: Nakaya, Y, et al.
Publicado: (2014) -
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2017) -
Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021) -
Jak inhibitors in vitiligo: a meta analysis
por: Huang, Xinlyu, et al.
Publicado: (2023)